Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study DOI Open Access
Federica Tavaglione, Maral Amangurbanova, Alexander H. Yang

и другие.

Alimentary Pharmacology & Therapeutics, Год журнала: 2025, Номер unknown

Опубликована: Янв. 17, 2025

ABSTRACT Background The current subclassification of steatotic liver disease (SLD) relies on validated questionnaires, such as Alcohol Use Disorders Identification Test (AUDIT) and Lifetime Drinking History (LDH), which, while useful, are impractical lack precision for their use in routine clinical practice. Phosphatidylethanol (PEth) is a quantitative, objective alcohol biomarker with high sensitivity specificity. Aims To assess the diagnostic accuracy PEth differentiating metabolic dysfunction alcohol‐associated (MetALD) from dysfunction‐associated (MASLD) large, population‐based, prospective, multiethnic cohort individuals overweight or obesity. Methods This cross‐sectional analysis prospective study including 374 adults obesity residing Southern California who had SLD defined by MRI‐PDFF ≥ 5%. research visit included medical history, biochemical testing, standardised questionnaires (including AUDIT LDH), physical examination, advanced imaging using MRE. Results Among SLD, prevalence MASLD, MetALD, ALD was 90.1%, 6.4%, 3.5%, respectively. robust detection MetALD (AUROC 0.81, 95%CI 0.73–0.89) Youden cut‐off 25 ng/mL. In head‐to‐head comparative efficacy analysis, both statistically clinically superior to all previously used indirect biomarkers diagnosing aspartate aminotransferase/alanine aminotransferase ratio, mean corpuscular volume, gamma glutamyltransferase, ALD/NAFLD index ( p < 0.05). Conclusions outperforms non‐invasive tests MASLD has potential change practice enhancing SLD.

Язык: Английский

Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study DOI Open Access
Federica Tavaglione, Maral Amangurbanova, Alexander H. Yang

и другие.

Alimentary Pharmacology & Therapeutics, Год журнала: 2025, Номер unknown

Опубликована: Янв. 17, 2025

ABSTRACT Background The current subclassification of steatotic liver disease (SLD) relies on validated questionnaires, such as Alcohol Use Disorders Identification Test (AUDIT) and Lifetime Drinking History (LDH), which, while useful, are impractical lack precision for their use in routine clinical practice. Phosphatidylethanol (PEth) is a quantitative, objective alcohol biomarker with high sensitivity specificity. Aims To assess the diagnostic accuracy PEth differentiating metabolic dysfunction alcohol‐associated (MetALD) from dysfunction‐associated (MASLD) large, population‐based, prospective, multiethnic cohort individuals overweight or obesity. Methods This cross‐sectional analysis prospective study including 374 adults obesity residing Southern California who had SLD defined by MRI‐PDFF ≥ 5%. research visit included medical history, biochemical testing, standardised questionnaires (including AUDIT LDH), physical examination, advanced imaging using MRE. Results Among SLD, prevalence MASLD, MetALD, ALD was 90.1%, 6.4%, 3.5%, respectively. robust detection MetALD (AUROC 0.81, 95%CI 0.73–0.89) Youden cut‐off 25 ng/mL. In head‐to‐head comparative efficacy analysis, both statistically clinically superior to all previously used indirect biomarkers diagnosing aspartate aminotransferase/alanine aminotransferase ratio, mean corpuscular volume, gamma glutamyltransferase, ALD/NAFLD index ( p < 0.05). Conclusions outperforms non‐invasive tests MASLD has potential change practice enhancing SLD.

Язык: Английский

Процитировано

8